Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Metastatic soft tissue or bone sarcoma

• 18 years of age or older

• Adequate blood counts

• Adequate kidney and liver function

• At least 1 but no more than 3 prior systemic therapy regimens for this cancer

• Good performance status - able to carry out work of a light or sedentary nature

Exclusion Criteria:

• Pre-existing hear disease such as congestive heart failure, or arrhythmia known to increase the risk of thromboembolic events (blood clots)

• Blood clot in the last 6 months, known clotting problem or platelet disorder

• History of brain cancer